HRT Financial’s Alterity Therapeutics ATHE Stock Holding History

HRT Financial’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,138	Closed	-$6K	–	2777
2022 Q2	$6K	Buy	+1,138	New	+$8.07K	﹤0.01%	2723
2021 Q4	–	Sell	-1,061	Closed	-$13K	–	3159
2021 Q3	$13K	Sell	1,061 -1,738	-62%	-$24.2K	﹤0.01%	3172
2021 Q2	$36K	Buy	+2,799	New	+$37.9K	﹤0.01%	2699

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCA

Providence Capital Advisors Charlotte, North Carolina $613M AUM 17.83% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

HRT Financial's ATHE Position: Q3 2022 in Review

HRT Financial sold out of Alterity Therapeutics (ATHE) in Q3 2022, closing a stake of 1,138 shares — an estimated $6K sold.

HRT Financial first reported a position in ATHE in Q2 2021 and held it in 3 quarters. The position peaked at $36K in Q2 2021. 9 funds tracked by Wall St. Rank hold ATHE as of Q3 2022.

HRT Financial reported no remaining Alterity Therapeutics position as of Q3 2022 after selling out during the quarter.
HRT Financial sold 1,138 Alterity Therapeutics shares in Q3 2022, an estimated $6K.
HRT Financial first reported a position in Alterity Therapeutics in Q2 2021 and held it in 3 quarters.
HRT Financial's Alterity Therapeutics position peaked at $36K in Q2 2021.
9 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.